Cost, Speed, and Quality- Emerging opportunities for Drug Discovery in Asia
Date/Location: May 14th, 2008 at the Holiday Inn, Woburn, MA
News
WOBURN and Weston, Mass., May 6, 2008 – CreaGen Biosciences, Inc. and ProXyChem, LLC announced today that the two companies have entered into an agreement to combine their expertise in offering comprehensive Structure-Based Drug Design (SBDD) and lead optimization services. Drug discovery research is a complex, time-consuming activity that interweaves multiple scientific disciplines on the path to creating new treatments for human diseases. While once virtually the exclusive province of large pharmaceutical companies, large numbers of small pharmaceutical and biopharmaceutical start-ups have entered the drug discovery field. Medicinal Chemistry and SBDD operations require specialized skills and expensive infrastructure, leading many small companies to outsource some or all of these operations. CreaGen and ProXyChem have teamed up to provide their complementary capabilities to client companies as a seamlessly integrated Medicinal Chemistry and SBDD service.
Dr. Rajur chaired the medicinal chemistry symposium of the Northeastern section of American Chemical Society, Holiday Inn Hotel, Woburn, MA, on December 12th, 2007. Symposium title “Signal Transduction Targets and Drug Discovery“.
Dr. Rajur chaired the medicinal chemistry symposium of the Northeastern section of American Chemical Society, Emmanuel College, Boston, MA, May 17th , 2007. Symposium title “Lead Optimization Strategies“.
Dr. Rajur participated in American Chemical Society’s 233rd National Meeting held March 25-29, 2007, Chicago, IL
Dr. Rajur participated in “Partnering and Outsourcing Models in Biology and Preclinical R&D” held February 20-21, 2007 at San Diego Marriott, Mission Valley, San Diego, CA.
BOSTON–(BUSINESS WIRE)–The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.
For the past three years, Mercury has partnered with CreaGen for medicinal chemistry-based outsourcing of their lead generation program seeking to develop small molecule activators of AMP activated protein kinase. Novel AMPK activators hold promise for the treatment of type 2 diabetes, cardiovascular disease, and cancer.
Dr. Rajur participated in “Partnering and Outsourcing Models in Biology and Preclinical R&D” held February 20-21, 2007 at San Diego Marriott, Mission Valley, San Diego, CA. Dr. Rajur participated in American Chemical Society’s 233rd National Meeting held March 25-29, 2007, Chicago, IL Dr. Rajur chaired the medicinal chemistry symposium of the Northeastern Section of American Chemical Society, Emmanuel College, Boston, MA, May 17th , 2007. Symposium: “Lead Optimization Strategies”. CreaGen presented two papers at the American Chemical Society’s 234th National Meeting held August 19-23, 2007, Boston, MA Dr. Rajur chaired the medicinal chemistry symposium of the Northeastern section of American Chemical Society, Holiday Inn Hotel, Woburn, MA, on December 12th, 2007. Symposium: “Signal Transduction Targets and Drug Discovery”.
Contact us
Call us
Visit us anytime
Send us an email
Links
Subscribe
Sign up for CreaGen Inc newsletter to receive all the news.
Contact us
Call us
Visit us anytime
Send us an email
Links
Subscribe
Sign up for Medicare newsletter to receive all the news offers and discounts from Medicare eye clinic.